Retraction: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer’s therapeutics

Following publication, the publisher found evidence of peer review manipulation. As the scientific integrity of the article cannot be guaranteed, and in adherence to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.

This retraction was approved by the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and had a chance to respond. This communication has been recorded by the publisher.

Frontiers would like to thank the concerned reader who contacted us regarding the published article and the users on PubPeer for bringing the published article to our attention.

Citation: Frontiers Editorial Office (2024) Retraction: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer’s therapeutics. Front. Aging Neurosci. 16:1399271. doi: 10.3389/fnagi.2024.1399271

Received: 11 March 2024; Accepted: 11 March 2024;
Published: 28 March 2024.

Copyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org